Research graph
References from Cutaneous adverse events with antibody-drug conjugates: a FAERS-based pharmacovigilance study. Local targets link to admitted publications; unresolved targets remain external evidence.
Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies.
10.3322/caac.21705 · 2022 · External reference
Antibody drug conjugates: lessons from 20 years of clinical experience.
10.1093/annonc/mdw424 · 2016 · External reference
Antibody-Drug conjugates: a comprehensive review.
10.1158/1541-7786.mcr-19-0582 · 2020 · External reference
Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric Cancer.
10.1056/nejmoa2503119 · 2025 · External reference
Sacituzumab govitecan in untreated, advanced triple-negative Breast Cancer.
10.1056/nejmoa2511734 · 2025 · External reference
Strategies and challenges for the next generation of antibody-drug conjugates.
10.1038/nrd.2016.268 · 2017 · External reference
Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.
10.1186/s12943-025-02489-2 · 2025 · External reference
Treatment-related adverse events of antibody drug-conjugates in clinical trials.
10.1186/s13045-025-01720-3 · 2025 · External reference
Dermatologic toxicities of antibody-drug conjugates.
10.1016/j.jaad.2024.08.036 · 2024 · External reference
Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis.
10.1002/cncr.34507 · 2023 · External reference
Enfortumab vedotin in previously treated advanced urothelial carcinoma.
10.1056/nejmoa2035807 · 2021 · External reference
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.
10.1016/j.esmoop.2025.105082 · 2025 · External reference
Optimizing the safety of antibody-drug conjugates for patients with solid tumours.
10.1038/s41571-023-00783-w · 2023 · External reference
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates administered via subcutaneous and intratumoral routes.
10.3390/pharmaceutics15041132 · 2023 · External reference
Data mining of the public version of the FDA adverse event reporting system.
10.7150/ijms.6048 · 2013 · External reference
A Bayesian neural network method for adverse drug reaction signal generation.
10.1007/s002280050466 · 1998 · External reference
A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
10.3389/fphar.2023.1259908 · 2023 · External reference
Signal mining and analysis of influencing factors for adverse events of Nivolumab and Cetuximab in the treatment of head and neck cancer based on the US FAERS database.
10.3389/fimmu.2025.1658535 · 2025 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2025 · External reference
Avoiding delays in reporting time-to-event randomized trials: calendar backstops and other approaches.
10.1200/jco.24.00025 · 2024 · External reference
Infectious adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FAERS database.
10.3389/fimmu.2025.1647944 · 2025 · External reference
Targeting HER2-positive breast cancer: advances and future directions.
10.1038/s41573-022-00579-0 · 2023 · External reference
Global trends and forecasts of breast cancer incidence and deaths.
10.1038/s41597-023-02253-5 · 2023 · External reference
Tisotumab vedotin: first approval.
10.1007/s40265-021-01633-8 · 2021 · External reference
Profile of enfortumab vedotin in the treatment of urothelial carcinoma: the evidence to date.
10.2147/dddt.s240854 · 2021 · External reference
Regulatory roles of androgens in cutaneous wound healing.
10.1160/th03-05-0302 · 2003 · External reference
Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression.
10.1172/jci39335 · 2009 · External reference
Drug-induced cutaneous toxicities in solid tumor oncology: mechanisms, manifestations, and management.
10.1007/s12032-025-03193-3 · 2025 · External reference
Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates.
10.1124/dmd.114.058586 · 2014 · External reference
Whole-Body pharmacokinetics and physiologically based pharmacokinetic Model for Monomethyl Auristatin E (MMAE).
10.3390/jcm10061332 · 2021 · External reference
Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions.
10.1016/s0009-9236(97)90166-1 · 1997 · External reference
Langerhans cells express human β-defensin 3: relevance for immunity during skin ageing.
10.1111/bjd.16770 · 2018 · External reference
The analysis of key factors related to ADCs structural design.
10.3389/fphar.2019.00373 · 2019 · External reference
Stepping forward in antibody-drug conjugate development.
10.1016/j.pharmthera.2021.107917 · 2022 · External reference
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial Cancer.
10.1056/nejmoa2312117 · 2024 · External reference
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
10.1016/j.annonc.2023.08.016 · 2023 · External reference
Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial Cancer: a single-center experience and review of the literature.
10.1016/j.euros.2023.01.002 · 2023 · External reference
Postmarketing cases of enfortumab vedotin-associated skin reactions reported as stevens-johnson syndrome or toxic epidermal necrolysis.
10.1001/jamadermatol.2021.3450 · 2021 · External reference
Nectin-4 mutations causing ectodermal dysplasia with syndactyly perturb the rac1 pathway and the kinetics of adherens junction formation.
10.1038/jid.2014.119 · 2014 · External reference
Antibody-drug conjugates: a review of cutaneous adverse effects.
10.1016/j.jaad.2024.07.1463 · 2024 · External reference
Blistering lesions associated with loncastuximab tesirine.
10.1001/jamadermatol.2022.1389 · 2022 · External reference
Management of adverse reactions to loncastuximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
10.1002/hon.70128 · 2025 · External reference
Diffuse telangiectatic rash associated with novel antibody drug conjugate therapies.
10.1001/jamadermatol.2020.0208 · 2020 · External reference
Loncastuximab tesirine in the treatment of relapsed or refractory diffuse large B-cell lymphoma.
10.3390/ijms25147580 · 2024 · External reference
T-DM1-related telangiectasias: a potential role in secondary bleeding events.
10.1093/annonc/mdu533 · 2015 · External reference
Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: a case report.
10.1016/j.chest.2015.09.008 · 2016 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2017 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
2019 · External reference
Gemtuzumab ozogamicin.
10.2165/00003495-200161090-00007 · 2001 · External reference
Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin.
10.1093/oncolo/oyac001 · 2022 · External reference
Skin toxicity of enfortumab vedotin: proposal of a specific management algorithm.
10.1111/jdv.19454 · 2024 · External reference
Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities.
10.1002/onco.13878 · 2021 · External reference
